Dexcom added approximately 500,000 to 600,000 net users to its worldwide customer base, excluding Stelo customers, demonstrating strong organic growth and market penetration. This expansion is a key driver of revenue growth.

Dexcom launched Stelo, a new biosensor designed for adults with prediabetes and Type 2 diabetes who do not use insulin, marking a significant expansion into a new market segment. This strategic move diversifies Dexcom's product offerings and addresses a broader patient population.

Dexcom continues to pursue growth opportunities in sales outside the United States, especially in Asia and Europe. This international expansion is a key component of Dexcom's long-term growth strategy and diversifies its revenue streams.

Operating expenses increased by 9% due to higher headcount, increased advertising and marketing costs, and increased software and data costs. This reflects ongoing investments in growth initiatives and infrastructure.

Despite experiencing manufacturing and inventory challenges for G7, Dexcom continued to meet market demand and expand its customer base. This demonstrates effective supply chain management and operational resilience.

Research and development expenses increased by 9%, reflecting Dexcom's commitment to innovation and future product development. These investments are crucial for maintaining a competitive edge and expanding product capabilities.

The company anticipates experiencing decreasing prices for their products due to pricing pressure from managed care organizations and other third-party payors, which could impact their profitability if they are unable to reduce expenses.

The company has recently experienced manufacturing and inventory challenges for G7 that have resulted, and may continue to result from time to time, in disruptions in their ability to supply certain markets.

The company is subject to cybersecurity risks and cyber incidents that could result in the compromise of confidential data or critical data systems and give rise to potential harm to customers, remediation and other expenses, expose them to liability under HIPAA, consumer protection laws, or other common law theories, subject them to litigation and federal and state governmental inquiries, damage their reputation, and otherwise be disruptive to their business and operations.

Dexcom competes directly with the Diabetes Care division of Abbott Laboratories; Medtronic plc's Diabetes Group; Roche Diabetes Care, a division of Roche Diagnostics; privately-held LifeScan, Inc.; and Ascensia Diabetes Care, each of which manufactures and markets products for the single-point finger stick device market.

Several companies are developing or commercializing products for continuous or periodic monitoring of glucose levels in the interstitial fluid under the skin that compete directly with Dexcom's products. They have competed with Abbott for several years and their Libre family of CGM products.

Dexcom believes that the principal competitive factors in their market include safe, reliable and high-quality performance of products; cost of products and eligibility for reimbursement; comfort and ease of use of products; effective sales, marketing and distribution networks; brand awareness and strong acceptance by healthcare professionals, people with diabetes and those seeking to optimize metabolic health.

The company has recently experienced manufacturing and inventory challenges for G7 that have resulted, and may continue to result from time to time, in disruptions in their ability to supply certain markets, including in the U.S. and other countries.

The company depends upon third-party suppliers and outsource to other parties, making them vulnerable to supply disruptions, suboptimal quality, non-compliance and/or price fluctuations, which could harm their business.

Failure to comply with applicable regulatory requirements, including those applicable to the conduct of their clinical trials, can result in enforcement action by the FDA, which may lead to any of the following sanctions: warning letters or untitled letters that require corrective action; fines and civil penalties; unanticipated expenditures; delays in approving or refusal to approve their future continuous glucose monitoring systems or other products.

Dexcom is leveraging its technology platform with the goal of enhancing the capabilities of its current products (including obtaining expanded indications for use) and to develop additional CGM products. This demonstrates a focus on continuous innovation.

Dexcom continues to pursue and support development partnerships with insulin pump companies and companies or institutions developing insulin delivery systems, including automated insulin delivery systems. With the introduction of Stelo, they are also pursuing and supporting development partnerships with consumer technology product companies that seek to provide metabolic health insights to their customers.

Dexcom has developed technology for reliable transmission and reception and have consistently demonstrated a high rate of successful transmissions from transmitter to receiver or compatible mobile device in their clinical trials. This demonstrates the company's commitment to technological superiority.

Dexcom ended the year with a strong cash position, providing financial flexibility for future growth and strategic initiatives. This level of liquidity enables Dexcom to fund its operations and invest in new opportunities.

Dexcom is investing in new manufacturing facilities in Malaysia and Ireland to scale up manufacturing capacity. These investments are aimed at supporting future growth and meeting increasing demand for their products.

The Board of Directors authorized and completed a $750 million share repurchase program, reflecting management's confidence in the company's long-term prospects and commitment to returning value to shareholders.

The company has committed to operate their business in a manner that is environmentally sustainable and conserves natural resources and reduces waste. This demonstrates a commitment to environmental responsibility.

Dexcom is committed to quality and believe that is best achieved through a safe and healthy workplace as well as a Quality Management System that is compliant with all applicable regulatory requirements and which is continuously being improved.

The company expects all employees to foster a culture of accountability in line with their Code of Conduct and Business Ethics. They also maintain a compliance program to help enforce ethical conduct and adherence to applicable laws and regulations.

The healthcare industry is subject to various U.S. federal and state laws pertaining to healthcare fraud and abuse. Violations of these laws are punishable by criminal and civil sanctions, including, in some instances, exclusion from participation in U.S. federal and state healthcare programs, including Medicare and Medicaid.

The company is subject to complex and evolving U.S. and international laws and regulations and other requirements regarding privacy, data protection, security, and other matters. Many of these laws and regulations are subject to change and uncertain interpretation, and could result in claims, changes to their business practices, monetary penalties, increased cost of operations, or declines in user growth or engagement, or otherwise harm their business.

The medical devices that the company manufactures are subject to regulation by numerous regulatory bodies, including the FDA and comparable international regulatory agencies. These agencies require manufacturers of medical devices to comply with applicable laws and regulations governing the development, testing, manufacturing, labeling, marketing and distribution of medical devices.